ID

28773

Beschreibung

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180; ODM derived from: https://clinicaltrials.gov/show/NCT00907998

Link

https://clinicaltrials.gov/show/NCT00907998

Stichworte

  1. 03.02.18 03.02.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

3. Februar 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Coronary Heart Disease NCT00907998

Eligibility Coronary Heart Disease NCT00907998

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
male and female chd or chd equivalent patients
Beschreibung

Gender | Coronary heart disease | Coronary heart disease Equivalent

Datentyp

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0010068
UMLS CUI [3,1]
C0010068
UMLS CUI [3,2]
C0205163
body mass index (bmi) must be within the range of 20 to 35 kg/m2,
Beschreibung

Body mass index

Datentyp

boolean

Alias
UMLS CUI [1]
C1305855
patient must have been on a stable statin therapy for >8 weeks prior to first dose except for the statin intolerant patients.
Beschreibung

Statin Stable | Exception Intolerance to Statin

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0360714
UMLS CUI [1,2]
C0205360
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C1744706
UMLS CUI [2,3]
C0360714
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
pregnancy
Beschreibung

Pregnancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
significant illness within two weeks prior to dosing.
Beschreibung

Illness Significant

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C0750502
triglycerides ≥ 500 mg/dl (5.65 mmol/l)
Beschreibung

Triglycerides measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C0202236
uncontrolled hypertension
Beschreibung

Uncontrolled hypertension

Datentyp

boolean

Alias
UMLS CUI [1]
C1868885
any condition that in the opinion of the investigator or the novartis medical monitor would jeopardize the evaluation of efficacy or safety.
Beschreibung

Condition compromises Evaluation Efficacy | Condition compromises Evaluation Safety

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C2945640
UMLS CUI [1,3]
C1261322
UMLS CUI [1,4]
C1280519
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C2945640
UMLS CUI [2,3]
C1261322
UMLS CUI [2,4]
C0036043
presence of nyha class iii or iv chronic heart failure
Beschreibung

Chronic heart failure New York Heart Association Classification

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0264716
UMLS CUI [1,2]
C1275491
mi or angioplasty (including stenting), acute coronary syndrome (acs), unstable angina or arterial embolic disease within 6 months prior to do other protocol-defined inclusion/exclusion criteria may apply
Beschreibung

Myocardial Infarction | Angioplasty | Stenting | Acute Coronary Syndrome | Angina, Unstable | Arterial embolism | Eligibility Criteria Study Protocol

Datentyp

boolean

Alias
UMLS CUI [1]
C0027051
UMLS CUI [2]
C0162577
UMLS CUI [3]
C2348535
UMLS CUI [4]
C0948089
UMLS CUI [5]
C0002965
UMLS CUI [6]
C0549124
UMLS CUI [7,1]
C1516637
UMLS CUI [7,2]
C2348563

Ähnliche Modelle

Eligibility Coronary Heart Disease NCT00907998

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Gender | Coronary heart disease | Coronary heart disease Equivalent
Item
male and female chd or chd equivalent patients
boolean
C0079399 (UMLS CUI [1])
C0010068 (UMLS CUI [2])
C0010068 (UMLS CUI [3,1])
C0205163 (UMLS CUI [3,2])
Body mass index
Item
body mass index (bmi) must be within the range of 20 to 35 kg/m2,
boolean
C1305855 (UMLS CUI [1])
Statin Stable | Exception Intolerance to Statin
Item
patient must have been on a stable statin therapy for >8 weeks prior to first dose except for the statin intolerant patients.
boolean
C0360714 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C1744706 (UMLS CUI [2,2])
C0360714 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])
Illness Significant
Item
significant illness within two weeks prior to dosing.
boolean
C0221423 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
Triglycerides measurement
Item
triglycerides ≥ 500 mg/dl (5.65 mmol/l)
boolean
C0202236 (UMLS CUI [1])
Uncontrolled hypertension
Item
uncontrolled hypertension
boolean
C1868885 (UMLS CUI [1])
Condition compromises Evaluation Efficacy | Condition compromises Evaluation Safety
Item
any condition that in the opinion of the investigator or the novartis medical monitor would jeopardize the evaluation of efficacy or safety.
boolean
C0348080 (UMLS CUI [1,1])
C2945640 (UMLS CUI [1,2])
C1261322 (UMLS CUI [1,3])
C1280519 (UMLS CUI [1,4])
C0348080 (UMLS CUI [2,1])
C2945640 (UMLS CUI [2,2])
C1261322 (UMLS CUI [2,3])
C0036043 (UMLS CUI [2,4])
Chronic heart failure New York Heart Association Classification
Item
presence of nyha class iii or iv chronic heart failure
boolean
C0264716 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
Myocardial Infarction | Angioplasty | Stenting | Acute Coronary Syndrome | Angina, Unstable | Arterial embolism | Eligibility Criteria Study Protocol
Item
mi or angioplasty (including stenting), acute coronary syndrome (acs), unstable angina or arterial embolic disease within 6 months prior to do other protocol-defined inclusion/exclusion criteria may apply
boolean
C0027051 (UMLS CUI [1])
C0162577 (UMLS CUI [2])
C2348535 (UMLS CUI [3])
C0948089 (UMLS CUI [4])
C0002965 (UMLS CUI [5])
C0549124 (UMLS CUI [6])
C1516637 (UMLS CUI [7,1])
C2348563 (UMLS CUI [7,2])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video